Medicine
Contrave Extended-Release 90 mg/8 mg extended-release tablet
Contrave Extended-Release 90 mg/8 mg extended-release tablet is a prescription medicine containing Bupropion and Naltrexone for oral use, marketed by Nalpropion Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F).
Key facts
- Active ingredient (INN)
- Bupropion and Naltrexone
- Brand
- Contrave Extended-Release
- Strength
- 90 mg/8 mg
- Dosage form
- Extended-release tablet
- Route
- Oral
- Packs
- 120 tablets
- Marketing authorisation holder
- Nalpropion Pharmaceuticals
- Manufacturer
- Nalpropion Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A08AA62 Bupropion and Naltrexone
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 22 October 2014
- Identifiers
- RxCUI 1551468, 1551474DailyMed set ID 485ff360-32c8-11df-928b-0002a5d5c51bNDC 51267-890Application NDA200063
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 120 tablet, extended release in 1 bottle | 51267-890-99 | Nalpropion Pharmaceuticals | 22 October 2014 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Bupropion and Naltrexone is a fixed-dose combination of an aminoketone and an opioid antagonist. It is available as extended-release tablets for oral use. MedsAcross supplies Bupropion and Naltrexone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Bupropion and NaltrexoneFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Contrave Extended-Release prescribing information (Nalpropion Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Mysimba: European public assessment report (EPAR) · European Medicines Agency
Need Contrave Extended-Release 90 mg/8 mg extended-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.